Investing.com — Pada hari Kamis, analis UBS mempertahankan peringkat Beli untuk Merck & Co. Inc. (NYSE:MRK) dengan target harga tetap sebesar $105,00. Analisis firma tersebut menyoroti kekhawatiran ...

Liputan6.com, Jakarta Pertumbuhan ekonomi di momen Lebaran 2025 ini diramal belum bisa mencuat, lantaran adanya pelemahan daya beli masyarakat. Padahal di tahun-tahun sebelumnya, momentum Ramadan dan ...

Merck licenses the protein, called berahyaluronidase alfa, from Alteogen. Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents.

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

Investing.com — Pada hari Selasa, saham Merck & Co Inc (NYSE: MRK) mempertahankan peringkat Beli dan target harga $115,00 dari Citi, menyusul pengumuman perjanjian lisensi baru. Kesepakatan dengan ...

Penurunan daya beli masyarakat Indonesia pada awal 2025 tengah menjadi sorotan. Dosen ekonomi menduga jika penurunan ini akibat precautionary saving. Apa itu? Fatkur Huda selaku Pakar Ekonomi ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Mer­ck has struck a li­cens­ing deal for a car­dio­vas­cu­lar drug with Jiang­su Hen­grui Phar­ma­ceu­ti­cals, the lat­est in a flood of Chi­na deals be­ing made by … ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...